永太科技(002326.SZ)稱正積極與吉利德公司等下游客户接洽 尋求可能的合作機會
格隆匯2月3日丨永太科技(002326.SZ)公佈，公司股票交易價格連續兩個交易日(2019年1月23日、2020年2月3日)收盤價格漲幅偏離值累計超過20%，根據《深圳證券交易所股票上市規則》的有關規定，屬於股票交易異常波動情況。
公司留意到，在新型冠狀病毒感染的肺炎疫情期間，股吧、投資者互動平台有投資者關注公司醫藥板塊的抗病毒藥物和中間體，包括莫西沙星的中間體、與吉利德的合作等，同時有相關公共媒體發佈了《永太科技接洽吉利德新冠病毒在研藥物中間體採購合作》等報道。相關媒體和投資者對肺炎疫情給予了高度關注，公司現對相關情況進行説明並風險提示如下：
公司主營業務中，醫藥產品涉及生產抗感染類、抗病毒類藥物及中間體，公司下游客户包括吉利德、拜爾、美國默克、恆瑞等國際及國內知名企業。公司與拜耳公司合作的主要產品包括用於治療呼吸道感染的莫西沙星的中間體等；公司與吉利德公司在產品研發、供應方面合作多年，包括抗丙肝病毒藥物索非布韋的中間體等。近期公司得知吉利德公司在研藥物Remdesivir(瑞德西韋)可用於治療新型冠狀病毒肺炎，公司正積極與吉利德公司等下游客户接洽，尋求可能的合作機會，但此次接洽是否能達成合作尚存在不確定性，且下游客户在研藥物的臨牀試驗和藥品獲批存在不確定性且需要一定的時間，敬請廣大投資者注意投資風險。
根據武漢協和醫院公佈的解決方案，包括莫西沙星、左氧氟沙星、阿莫西林等藥物可以用於相關治療，公司目前部分產品是莫西沙星、左氧氟沙星等喹諾酮類藥物的中間體，下屬子公司佛山手心製藥有限公司生產阿莫西林幹混懸劑；根據藥監部門對疫情防控用製劑品種統計要求，公司下屬子公司佛山手心製藥有限公司生產的醋酸潑尼鬆片在統計範圍內。公司將會根據下游客户需要積極供應相應的產品。
截至目前上述事項尚未對公司業績產生重大影響，未來可實現的業務規模尚存在不確定性，敬請廣大投資者注意投資風險。除上述説明事項，公司未發現公共傳媒報道了其他可能或已經對本公司股票交易價格產生較大影響的未公開重大信息；
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
